Cancer diagnosis and treatment at the Hospital Clínic de Barcelona Group is composed of a team of experts in radiology, pathology, cancer surgery, chemotherapy, radiotherapy, care management and symptom care, who work together in multidisciplinary oncology teams.

The service began its activity in 1974 to meet the new requirements of cancer care and was the first Spanish centre to perform an allogeneic transplant in 1976.

The progressive improvement in the health system of our country has meant that more and more centres are performing conventional therapies. That is why our team has directed its efforts towards highly complex transplant programs, in accordance with the strongly consolidated culture of research, innovation and progress of our institution. Over the years, our high standards have allowed us to improve the quality of patient care and we have achieved a solid position in Spain and Europe.

In the barnaclínic+ Hematology Unit, we have specialists in the treatment of both malignant and non-malignant hematological diseases. We have specific treatment units for:

Lymphoproliferative diseases, monoclonal gammopathies, acute leukaemia and myelodysplasias, for other hematological neoplasms, for chronic myeloproliferative syndromes, anaemias and other red blood cell disorders, haemostasis and thrombosis, spinal insufficiency and platelet disorders (excluding haemostasis).

We also have specialized treatment units such as the Hematopoietic Stem Cell Transplantation Unit and the CAR-T Therapy Unit.

Our professionals in Hematology have a profound research vocation, which encompasses both the clinical and translational aspects. It takes place in the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Josep Carreras Leukaemia Research Institute (IJC), in collaboration with various prestigious national and international centres in this field.

In addition to conventional therapies, we are a centre that pioneers the development and application of innovative therapies. The Hematology service has a clinical trials area (Intherunit), where intense activity is carried out in the treatment of patients with new therapies. The unit offers 100 different trials per year for different types of cancer, with an average of 300 patients included.

CAR-T therapy is one of the most personalized medications in the treatment of cancer. In a first phase, T lymphocytes, white blood cells that are responsible for the immune response, are extracted from the patient's blood. Later, in the laboratory, these T lymphocytes are genetically reprogrammed and, finally, they are reintroduced into the patient so that they can recognize and attack tumour cells, without harming healthy ones.

Our CAR-T ARI-001 has been approved for the treatment of patients over 25 years of age affected by lymphoblastic leukaemia who do not respond to existing, conventional treatment. Studies have shown that CAR-T ARI-001 is safe and highly effective, with results comparable to those reported for other CAR-T therapies.

Our team of doctors, nurses, and other cancer experts will create a plan that is tailored to the patient's needs, focusing on personalized care. For this reason, we offer state-of-the-art cancer treatment, from an integrative perspective. We work in a multidisciplinary way, in a group made up of: Haematologists, Hematopathologists, Nurses, Physiotherapists, Geneticists, Psychologists and psychiatrists, Nutritionists, Social workers, Pharmacologists, Oncologists, radiotherapists, and specialists from other fields (cardiology - pulmonology - nephrology - dermatology - gastroenterology).

Our nursing team has training and specialization in the care of patients with hematological diseases. The work of the specialised nursing staff allows us, among other things, to successfully carry out the hematopoietic stem cell transplantation, CAR-T therapy and Home Care programs.